Latin American dementia-prevention study replicates POINTER outcomes at AAIC
A study testing lifestyle-based dementia risk-reduction strategies in Latin America has been called a "landmark" effort after its findings replicated the direction of the U.S. POINTER trial, according to Day 2 reporting from the Alzheimer's Association International Conference. The Alzheimer's Association's Maria Carrillo announced at Monday's plenary that 10,200 attendees from 115 countries are present this year, 1,700 more than last year's conference. For a disease that has proven intractable to treat, a behavioral finding that holds across two independent trials and two separate populations is a different kind of signal than a single-study result.
Key takeaways
- A Latin American lifestyle-based dementia risk-reduction study replicated the direction of benefit found in the U.S. POINTER trial, and was described as a "landmark" effort in Day 2 AAIC reporting.
- The U.S. POINTER trial found older at-risk adults in an intensive, structured program covering diet, exercise, and cardiovascular monitoring showed greater cognitive protection than those in a self-directed program.
- The Latin American study's full details—including enrollment size, specific endpoints, and effect sizes—are behind a STAT+ paywall and absent from the session summary.
- This year's Alzheimer's Association International Conference drew 10,200 attendees from 115 countries, 1,700 more than last year.
- Full publication of the Latin American study is the confirmable next milestone, enabling direct endpoint comparison with POINTER and independent peer review.
A study testing lifestyle-based dementia risk-reduction strategies in Latin America has been called a "landmark" effort after its findings replicated the direction of the U.S. POINTER trial, according to Day 2 reporting from the Alzheimer's Association International Conference. The Alzheimer's Association's Maria Carrillo announced at Monday's plenary that 10,200 attendees from 115 countries are present this year, 1,700 more than last year's conference. For a disease that has proven intractable to treat, a behavioral finding that holds across two independent trials and two separate populations is a different kind of signal than a single-study result.
What the POINTER trial found
The U.S. POINTER study, reported at last year's AAIC, set up two arms among older adults considered at risk for dementia. One group followed an intensive, structured program covering improved diet, exercise, cardiovascular health monitoring, and additional steps. The second group navigated a lower-intensity program on their own. Both arms saw some benefits. Participants in the intensive program showed greater protection of cognitive function than those in the self-directed group.
That result built on a recognized set of modifiable risk factors. Poor nutrition, poor sleep, limited cardiovascular health, physical inactivity, low social engagement, and lower education levels each carry documented associations with higher Alzheimer's risk. POINTER's design addressed those factors together rather than one at a time.
What the replication adds
Reproducing a direction of benefit in a geographically and demographically distinct cohort takes a single-trial signal and gives it cross-population weight. The Latin American study's full details are behind a STAT+ paywall, meaning enrollment size, specific endpoints, and effect sizes are absent from the session summary. How closely the study's methodology mirrors POINTER's will matter when the paper reaches peer review. A p-value in one population is a clue. The same direction reproduced elsewhere starts to look like a pattern worth building on.
What to watch
Additional data presentations are expected through the week at AAIC. STAT signaled conference coverage for Tuesday morning around 9:15 a.m. Eastern at statnews.com, with a newsletter wrap-up planned for Wednesday. The confirmable next milestone is full study publication, which would allow a direct comparison of endpoints between the Latin American replication and the original POINTER trial and put the methodology in front of independent review.
Filed by the newsroom of MarketPR on July 13, 2026. Source: MarketPR. Indicative figures are not investment advice.